Amgen cholesterol drug could get EU green light this week

Amgen cholesterol drug could get EU green light this week

Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart attacks compared to standard treatment alone. According to an agenda posted on the European …

12
Like
Save

Comments

Comments are disabled for this post.